Loading…
Loading…
Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bank of New York Mellon Corp lessened its holdings in Incyte Corporation (NASDAQ: INCY) by 1.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 989,709 shares of the biopharmaceutical company's stock after selling 12,540 shares during the period. Bank of New York
Fifth Third Bancorp boosted its stake in shares of Incyte Corporation (NASDAQ: INCY) by 145.2% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 27,289 shares of the biopharmaceutical company's stock after buying an additional 16,160 shares during the quarter. Fifth Third Bancorp's
Andra AP fonden lessened its position in Incyte Corporation (NASDAQ: INCY) by 34.6% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 259,048 shares of the biopharmaceutical company's stock after selling 137,252 shares during the quarter. Andra AP fonden owned about 0.13%
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets SAN DIEGO, July 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs), utilizing Halozyme's proprietary ENHANZE® drug delivery technology. The collaboration will focus on the potential for ENHANZE® to strengthen the subcutaneous formulation currently in development for INCA033989, with the goal of enabling more convenient delivery and dosing regimens that may improve the treatment experience.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Data to Be Highlighted in Four Rapid Oral Presentations at ESMO 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers.
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarciba
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for INCY and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.